Dyadic net loss widens 18.8% to USD 2.12 million in Q2 FY26; revenue slips 0.6% to USD 961,138
DYAI•Quarterly financial results
Dyadic posted a GAAP net loss of USD 2.12 million, unchanged at USD 0.06 per share.
Revenue slipped 0.6% to USD 961,138, as grant revenue rose USD 334,071 while R&D revenue fell USD 89,563.
Operating loss widened 18.8% to USD 2.05 million, on a 60.4% jump in cost of revenue to USD 984,165.
Expense trends and operational updates
R&D expenses dropped 47.2% to USD 332,621, while G&A climbed 17.6% to USD 1.69 million on higher rebranding and business development costs.
Quarter updates cited shipments of six recombinant proteins, initial pilot sales for cultivated meat, and an about 80% transferrin productivity gain.
